Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Sells Sequencing Business to Agencourt

NEW YORK, Feb. 25 - Genome Therapeutics has signed an agreement to sell its GenomeVision custom sequencing service business to Agencourt Bioscience, the companies said today.


Under the agreement, the Waltham, Mass., company  will transfer some of its sequencing equipment and personnel, as well as existing government and commercial accounts, to Agencourt, of Beverly, Mass.In return, Genome Therapeutics will receive a percentage of the revenues from the accounts for two years, as well as an undisclosed equity stake in Agencourt.


Lynn Doucette-Stamm, who heads up the GenomeVision services sector at Genome Therapeutics, will move to Agencourt as vice president of business development. 


Genome Therapeutics expects to eliminate 60 positions through this move, reducing its headcount to 95. Employees in the GenomeVision area will go through an interview process before being selected for jobs at the new Agencourt division, the company said.


Genome Therapeutics, however, will retain all rights to its PathoGenome database.


With this move, Genome Therapeutics said it hopes to hold its 2003 losses to $20 to $25 million for the year, as it previously projected.



The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.